Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | PPM1D | O15297 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1498725 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1498724 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9753069 | 0.92 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15046764 | 0.92 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL19148890 | 0.88 | SMN1; SMN2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22357286 | 0.88 | SMN1; SMN2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16167661 | 0.88 | SMN1; SMN2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL17762361 | 0.87 | PPM1D (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18338419 | 0.86 | PPM1D (0.34) | PPM1D | |
| SCHEMBL18338417 | 0.86 | PPM1D (0.34) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11427561-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3405465-B1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3884940-A1 | NOVEL IMIDAZOLE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2021-09-29 | — | — | EP | disclosed |
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3405465-A1 | IRAK4 INHIBITING AGENTS | Biogen MA Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127430-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002279-A1 | NOVEL IMIDAZOLE DERIVATIVE | SLC11A2, MLX, LPXN | CHRNB2 4635/4885CHRNA4 4653/4885CHRNB4 4654/4885 |
| US-11427561-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | CHRNB2 4487/4885CHRNA4 2398/4885CHRNB4 3315/4885 |
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | CHRNB2 4487/4885CHRNA4 2398/4885CHRNB4 3315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.